Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

• Status: Recruiting
• Trial end date: 2026-01-31
• Target enrollment: 0
• Participant gender: Female

Summary

This is a prospective, phase 3 randomized controlled clinical trial. Cervical cancer patients who undergo radical surgery but do not meet criteria of adjuvant therapy according to NCCN guideline are enrolled to receive adjuvant chemotherapy. The primary endpoint was disease-free survival (DFS) rate at 3 year. The secondary endpoints were 5-year DFS, overall survival (OS) and safety.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Huazhong University of Science and Technology
• Collaborators: First Affiliated Hospital of Chongqing Medical University; Hunan Cancer Hospital; Obstetrics & Gynecology Hospital of Fudan University; Qilu Hospital of Shandong University; The Third Xiangya Hospital of Central South University; Women's Hospital School Of Medicine Zhejiang University
• Treatments: Carboplatin; Docetaxel; Paclitaxel

Criteria

Inclusion Criteria:

1. Patients with 2018 FIGO staged IB1，IB2, IIA1 cervical cancer.

2. The initial treatment was radical hysterectomy + pelvic lymphadenectomy by laparotomy or laparoscopy with cervical cancer foci sealed before dissection of the vagina and without uterine manipulator.

3. Postoperative pathological diagnosis was cervical squamous cell carcinoma, cervical adenosquamous cell carcinoma or cervical adenocarcinoma.

4. Assessment of risk factors not meeting Sedlis criteria （NCCN guideline），but having one of following factors ：（1）Deep stromal infiltration（≥2/3 layer）；（2）histopathological differentiation grade G2 ~ G3；（3）Lymph-vascular space invasion ；（4）Adenocarcinoma or adenosquamous cell carcinoma；（5）Tumor size ≥2cm.

5. Age：18-70 years old.

6. WBC≥3.5*10^9/L, NEU≥1.5*10^9/L, Platelet≥80×10^9 /L; AST and ALT ≤1.5 times normal upper limit; Total bilirubin ≤1.5 times the upper limit of normal value; serum creatinine and blood urea nitrogen ≤the upper limit of normal value.

7. Eastern Cooperative Oncology Group score 0-1.

8. Well-compliance and willing to keep in touch.

9. Willing to participate in this study, and sign the informed consent.

Exclusion Criteria:

1. Postoperative pathology has high-risk factors（lymph node metastasis, parametrial infiltration or positive surgical margin）or meets Sedlis criteria.

2. Participate in other clinical trials at the same time.

3. Comorbidity including but not limited to: heart diseases (grade III-IV cardiac insufficiency (NYHA standard); central nervous system diseases or nonfunctional behavior; hematological system diseases; liver or kidney malformation or history of surgery.

4. Persons without disposing capacity.

5. Drug and/or alcohol abuse.

6. Unable or unwilling to sign informed consents.

7. Not eligible for the study judged by researchers.